Free Trial
OTCMKTS:ELTP

Elite Pharmaceuticals (ELTP) Stock Price, News & Analysis

Elite Pharmaceuticals logo
$0.53 +0.02 (+3.46%)
As of 05/23/2025 03:59 PM Eastern

About Elite Pharmaceuticals Stock (OTCMKTS:ELTP)

Key Stats

Today's Range
$0.51
$0.53
50-Day Range
$0.32
$0.54
52-Week Range
$0.16
$0.75
Volume
591,696 shs
Average Volume
944,006 shs
Market Capitalization
$565.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. Elite Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in Northvale, New Jersey.

Receive ELTP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elite Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ELTP Stock News Headlines

Elite Pharmaceuticals Gains FDA Approval for Generic Vyvanse
Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new blockchain development…
Elite Pharmaceuticals Reports Strong Q2 2025 Financial Results
See More Headlines

ELTP Stock Analysis - Frequently Asked Questions

Elite Pharmaceuticals' stock was trading at $0.5411 at the beginning of 2025. Since then, ELTP shares have decreased by 2.2% and is now trading at $0.5294.
View the best growth stocks for 2025 here
.

Elite Pharmaceuticals, Inc. (OTCMKTS:ELTP) issued its quarterly earnings results on Thursday, February, 13th. The specialty pharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter. Elite Pharmaceuticals had a negative trailing twelve-month return on equity of 6.92% and a negative net margin of 25.70%.
Read the conference call transcript
.

Shares of ELTP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Elite Pharmaceuticals investors own include Research Frontiers (REFR), Co-Diagnostics (CODX), Novavax (NVAX), FuelCell Energy (FCEL), Onconova Therapeutics (ONTX), iBio (IBIO) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
2/13/2025
Today
5/27/2025
Next Earnings (Estimated)
6/30/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:ELTP
Employees
40
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$20.11 million
Pretax Margin
-24.76%

Debt

Sales & Book Value

Annual Sales
$56.62 million
Cash Flow
$0.03 per share
Price / Cash Flow
16.94
Book Value
$0.03 per share
Price / Book
17.65

Miscellaneous

Outstanding Shares
1,068,363,000
Free Float
914,305,000
Market Cap
$565.59 million
Optionable
Not Optionable
Beta
0.04
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (OTCMKTS:ELTP) was last updated on 5/27/2025 by MarketBeat.com Staff
From Our Partners